Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Favourable Prognostic Significance of HER2 Mutations in Canine Pulmonary Adenocarcinoma Following Surgical Resection.
Ichimata M et al.
Veterinary and Comparative Oncology, 2025
Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report.
Nishihara M et al.
Thoracic Cancer, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer.
Sharma S et al.
Jco Global Oncology, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.
Liu D et al.
Cancer Research Communications, 2025
Decoding the functional impact of the cancer genome through protein-protein interactions.
Fu H et al.
Nature Reviews. Cancer, 2025
Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports.
Meng Y et al.
Frontiers in Immunology, 2025
The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population.
Erices JI et al.
Frontiers in Oncology, 2025
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
Waliany S et al.
Cancer Medicine, 2024
Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies.
Cavagna RO et al.
The Oncologist, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L et al.
Npj Precision Oncology, 2024
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.
Moorthi S et al.
Jci Insight, 2024
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Yang G et al.
Discover Oncology, 2024
HER2 mutation as an emerging target in advanced breast cancer.
Bon G et al.
Cancer Science, 2024
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT et al.
The Lancet. Oncology, 2024
Lung cancer in patients who have never smoked - an emerging disease.
LoPiccolo J et al.
Nature Reviews. Clinical Oncology, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF et al.
Gynecologic Oncology, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
Farinea G et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.
Lee K et al.
Scientific Reports, 2023
A review of HER2 overexpression and somatic mutations in cancers.
Galogre M et al.
Critical Reviews in Oncology/hematology, 2023
Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research.
Cardillo AB et al.
Annals of Medicine and Surgery (2012), 2023
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
Family Matters: Germline Testing in Thoracic Cancers.
Hathaway F et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 2023
Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.
Ahn BC et al.
Cancer Research and Treatment, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC et al.
Cancer Treatment and Research Communications, 2023
The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R et al.
Frontiers in Genetics, 2023
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.
Luo L et al.
Pigment Cell & Melanoma Research, 2022
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation.
Serna-Blasco R et al.
Cancers, 2022
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.
Ceyhan-Birsoy O et al.
Genome Medicine, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Wilding B et al.
Nature Cancer, 2022
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S et al.
Current Oncology (toronto, Ont.), 2022
Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling.
Testa U et al.
Expert Review of Molecular Diagnostics, 2022
Clinicopathologic features and treatment advances in cancers with HER2 alterations.
Cen S et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2021
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
Xu H et al.
World Journal of Surgical Oncology, 2021
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B et al.
Lung Cancer (amsterdam, Netherlands), 2021
Molecular pathogenesis of hereditary lung cancer: a literature review.
Rammal S et al.
Pharmacogenomics, 2021
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility.
Bao R et al.
Cancer Prevention Research (philadelphia, Pa.), 2021
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Abdel-Wahab R et al.
Scientific Reports, 2020
Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study.
Shi L et al.
Esmo Open, 2020
Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.
Huo R et al.
The Oncologist, 2020